Zenas BioPharma IPO

www.zenasbio.comHealthcare / BioTech & Pharma

Zenas BioPharma is a biopharmaceutical company that aims to develop inflammatory and immunology therapies. The company has a mission to address the unmet needs of patients who experience autoimmune and rare diseases by discovering differentiated approaches to current treatments. The company's lead product candidate is obexelimab, which is a bifunctional monoclonal antibody that was designed to inhibit B-cell activity. Zenas BioPharma was founded in 2019 by Lonnie Moulder Jr. and is headquartered in Waltham, MA.

Buy or sell Zenas BioPharma stock Learn more about Zenas BioPharma stock

Learn more about Zenas BioPharma

Is Zenas BioPharma a publicly traded company?

Zenas BioPharma is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Will Zenas BioPharma go IPO?

Zenas BioPharma has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Zenas BioPharma's IPO price?

The IPO price for Zenas BioPharma will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in Zenas BioPharma pre-IPO?

Zenas BioPharma is privately held company and is not publicly traded, therefor investing in Zenas BioPharma pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my Zenas BioPharma shares?

To determine the value of your Zenas BioPharma shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Zenas BioPharma shares. You can also learn more about how to sell your private shares before getting started.

Can you sell Zenas BioPharma before it goes public?

Yes, you can seek to sell shares in Zenas BioPharma while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

When was Zenas BioPharma founded?

Zenas BioPharma was founded in 2020.

Who are Zenas BioPharma's major investors?

New Enterprise Associates

Norwest Venture Partners

Wellington Management

Bristol Myers Squibb

Longitude Capital

Perceptive Advisors

Rock Springs Capital

Vivo Capital

Delos Capital

ArrowMark Partners

Agent Capital

Pivotal bioVenture Partners

SR One Capital Management

Pivotal Life Sciences

Enavate Sciences

Federated Hermes

Lepu Biopharma

Quantum Ventures

Fairmount Funds Management

Quan Capital

Superstring Capital Management

Tellus BioVentures

Wuxi Biologics

Xencor

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.